Collplant Biotechnologies Ltd (CLGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Collplant Biotechnologies Ltd (CLGN) has a cash flow conversion efficiency ratio of -0.309x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.88 Million) by net assets ($9.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CLGN equity financing ratio to measure how much of total assets are equity-financed.
Collplant Biotechnologies Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Collplant Biotechnologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Collplant Biotechnologies Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Collplant Biotechnologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collplant Biotechnologies Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VH Global Sustainable Energy Opportunities PLC
LSE:GSEO
|
0.021x |
|
Professional Diversity Network Inc
NASDAQ:IPDN
|
0.126x |
|
Conduit Pharmaceuticals Inc.
NASDAQ:CDT
|
-0.015x |
|
Tarapur Transformers Limited
NSE:TARAPUR
|
1.083x |
|
Atlantic Sapphire As
OL:ASA
|
-2.484x |
|
Parkd Ltd
AU:PKD
|
-9.779x |
|
Destiny Media Technologies Inc
V:DSY
|
-0.110x |
|
Centogene N.V.
NASDAQ:CNTGF
|
N/A |
Annual Cash Flow Conversion Efficiency for Collplant Biotechnologies Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Collplant Biotechnologies Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Collplant Biotechnologies Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.46 Million | $-14.09 Million | -1.047x | -973.53% |
| 2023-12-31 | $28.34 Million | $-2.76 Million | -0.097x | +77.02% |
| 2022-12-31 | $32.28 Million | $-13.70 Million | -0.424x | -865.55% |
| 2021-12-31 | $45.12 Million | $2.50 Million | 0.055x | +105.58% |
| 2020-12-31 | $4.48 Million | $-4.45 Million | -0.994x | +28.73% |
| 2019-12-31 | $4.09 Million | $-5.70 Million | -1.395x | -445.61% |
| 2018-12-31 | $4.76 Million | $-1.22 Million | -0.256x | +86.54% |
| 2017-12-31 | $2.61 Million | $-4.97 Million | -1.900x | +49.26% |
| 2016-12-31 | $1.34 Million | $-5.02 Million | -3.745x | -152.18% |
| 2015-12-31 | $2.51 Million | $-3.72 Million | -1.485x | -64.13% |
| 2014-12-31 | $3.68 Million | $-3.33 Million | -0.905x | -84.26% |
| 2013-12-31 | $7.78 Million | $-3.82 Million | -0.491x | +46.58% |
| 2012-12-31 | $4.20 Million | $-3.86 Million | -0.919x | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more